Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$120.0 - $182.95 $240 - $365
2 Added 1.09%
185 $23,000
Q1 2024

May 15, 2024

BUY
$170.78 - $208.42 $31,252 - $38,140
183 New
183 $33.7 Million
Q4 2021

Aug 30, 2024

SELL
$247.59 - $304.47 $37,138 - $45,670
-150 Reduced 60.0%
100 $26.5 Million
Q3 2021

Aug 30, 2024

SELL
$194.77 - $324.21 $74,207 - $123,524
-381 Reduced 60.38%
250 $72.2 Million
Q2 2021

Aug 30, 2024

BUY
$165.87 - $220.95 $73,978 - $98,543
446 Added 241.08%
631 $126 Million
Q1 2021

Aug 30, 2024

SELL
$180.37 - $226.26 $4,509 - $5,656
-25 Reduced 3.95%
608 $118 Million
Q4 2020

Aug 30, 2024

BUY
$148.08 - $206.57 $55,233 - $77,050
373 Added 143.46%
633 $121 Million
Q2 2020

Aug 30, 2024

BUY
$94.33 - $140.48 $7,074 - $10,536
75 Added 40.54%
260 $32.1 Million

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.